Viewing data from:

TAZAROTENE

ANDA

TAZAROTENE | A213079 | PADAGIS ISRAEL PHARMACEUTICALS LTD

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: TAZORAC(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$6.77

per gm

Lowest NADAC/Unit

$5.82

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
45802044294TAZAROTENE 0.1% GEL	$6.77	GM	Generic	—	2026-06-17
45802043694TAZAROTENE 0.05% GEL	$5.82	GM	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 4 NDCs (4 FSS)

Lowest Price

$134.58

Highest Price

$484.54

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
45802-0436-01TAZAROTENE 0.05% GEL,TOP	$448.64	FSS	Padagis Sourcing Solutions LLC	09/30/2026
45802-0436-94TAZAROTENE 0.05% GEL,TOP	$134.58	FSS	Padagis Sourcing Solutions LLC	09/30/2026
45802-0442-01TAZAROTENE 0.1% GEL,TOP	$484.54	FSS	Padagis Sourcing Solutions LLC	09/30/2026
45802-0442-94TAZAROTENE 0.1% GEL,TOP	$145.36	FSS	Padagis Sourcing Solutions LLC	09/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain4 active DMFs4 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

ALIVUS LIFE SCIENCES LTDTAZAROTENE

DMF 214222008

PCASTAZAROTENE

DMF 251612011

TARO PHARMACEUTICAL INDUSTRIES LTDTAZAROTENE, MICRONIZED

DMF 284702014

OLON SPATAZAROTENE

DMF 296002015

CARDINAL HEALTH PTS LLCInactiveTAZAROTENE 1.5 MG AND 4.5 MG CAPSULES

DMF 168642003

BASF SEInactiveTAZAROTENE

DMF 190892006

WATSON PHARMA PRIVATE LTDInactiveTAZAROTENE

DMF 200632006

PIRAMAL HEALTHCARE CANADA LTDInactiveTAZAROTENE

DMF 248742011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 0.05%

0 patents0 exclusivities▴

GEL;TOPICAL | Approved: Apr 25, 2023

No patent or exclusivity listings for this strength.

#002 — 0.1%

0 patents0 exclusivities▾

GEL;TOPICAL | Approved: Apr 25, 2023